the content of {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-l-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazoline-4-yl} acetic acid.

7. The pharmaceutical composition according to any one of claims 1 to 6, characterized in that 100 ml of said composition comprises the following:

a) 0.2 - 2.0 g, preferably 0.5 - 1.25 g of {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazoline-4-yl} acetic acid or a salt, a solvate or a solvate of a salt thereof,

b) 2.5 g, preferably 0.5 - 1.5 g of ~~arginine~~cyclodextrin,

c) 1.5 - 9.5 g, preferably 2.0 - 4.75 g of glucose,

d) 0.6 - 4.0 g, preferably 0.75 - 2.0 g of NaH_2PO_4, and

e) water,

wherein said composition has a pH in the range of 7.5 to 8.5, preferably 7.7 to 8.0.

8. The pharmaceutical composition according to any one of claims 1 to 5, characterized in that the excipient is selected from the β-cyclodextrins and the modified β-cyclodextrins, in particular the hydroxyalkyl β-cyclodextrins, the alkylhydroxyalkyl β-cyclodextrins and the sulfoalkyl cyclodextrins.

9. The pharmaceutical composition according to claim 8, characterized in that said preparation, in relation to the content of {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid, contains 1 to 10 equivalents, preferably 2 to 7 equivalents, and in particular 2.5 to 5 equivalents of cyclodextrin as well as 0 to 2.0 equivalents, preferably 0.5 to 1.5 equivalents, and in particular 0.75 to 0.9 equivalents of NaOH.

10. The pharmaceutical composition according to any one of claims 1 to 5 or according to claims 8 or 9, characterized in that 100 ml of said composition comprises the following: